This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
https://www.barrons.com/articles/moderna-stock-price-covid-lymes-flu-vaccine-cc70b711
Updated April 11, 2023 9:11 am ET / Original April 11, 2023 8:57 am ET
Order Reprints
Print Article
Moderna
shares slid early Tuesday after the biotech company said it was too soon “to declare early success” in a flu vaccine trial, due to a lack of sufficient cases.
It was recommended the company continue testing.